GlassScriptPhysician profile
David Alexander Phaup
NPI 1942861877
$7,124.90
in general payments reported to CMS, 2019-2025
18 companies · $1,699 in 2025
The $1,699 reported for 2025 was more than what 96% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $588 · 2020: $344 · 2021: $530 · 2022: $1,547 · 2023: $640 · 2024: $1,777 · 2025: $1,699.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,711 · Travel and Lodging: $405.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,710.75 |
| Travel and Lodging | $404.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,654.35 | 2019-2025 | Precision 1, Total30, Precision7 |
| Tarsus Pharmaceuticals, INC. | $1,088.06 | 2024-2025 | Xdemvy |
| Glaukos Corporation | $529.11 | 2019-2025 | Idosetr |
| Johnson & Johnson Vision Care, INC. | $438.24 | 2021-2025 | Acuvue |
| Oyster Point Pharma, INC. | $370.56 | 2022-2025 | Tyrvaya |
| Abbvie INC. | $321.29 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $316.70 | 2022-2025 | Miebo, Xiidra |
| Coopervision INC. | $313.01 | 2020-2024 | Myday Contact Lens |
| Sun Pharmaceutical Industries INC. | $289.19 | 2022-2025 | |
| Dompe US, INC. | $198.19 | 2022-2025 | Oxervate |
| Novartis Pharmaceuticals Corporation | $148.34 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $121.90 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $110.04 | 2019 | |
| Biotissue Holdings INC. | $97.02 | 2023-2025 | |
| Sight Sciences, INC. | $60.89 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $34.14 | 2025 | Vevye |
| Leadiant Biosciences, INC. | $21.28 | 2025 | Cystaran |
| Visioneering Technologies, INC. | $12.59 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Phaup listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.